Pediatric study of ferumoxytol (feraheme) for treatment of iron deficiency anaemia in patients with chronic kidney disease

Trial Profile

Pediatric study of ferumoxytol (feraheme) for treatment of iron deficiency anaemia in patients with chronic kidney disease

Planning
Phase of Trial: Phase III

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Ferumoxytol (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2018 New trial record
    • 28 Mar 2018 In Dec 2016, the company proposed a protocol to FDA for a new pediatric study to satisfy post-approval commitments for feraheme. Following recent interactions with the FDA regarding the adequacy of proposed protocol, the company amended the protocol and intend to initiate a new pediatric study in the second quarter of 2018, According to AMAG Pharmaceuticals Form 10-K document.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top